Treatment-Resistant Epilepsies
Jazz Pharmaceuticals’ Epidiolex Fails to Meet Primary Endpoint in Japanese Phase 3 Trial for Treatment-Resistant Epilepsies
Jazz Pharmaceuticals, Epidiolex, Cannabidiol Oral Solution, Treatment-Resistant Epilepsies, Phase 3 Trial, Japan